Your browser doesn't support javascript.
loading
Treatment satisfaction of adult patients with moderate-to-severe atopic dermatitis treated with baricitinib in France, Germany, and the United Kingdom: results from a cross-sectional international patient survey.
Augustin, Matthias; Nosbaum, Audrey; Werfel, Thomas; Grond, Susanne; Reed, Catherine; Lampropoulou, Anastasia; Tietz, Nicole; Irvine, Alan D; Riedl, Elisabeth.
Afiliación
  • Augustin M; Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Nosbaum A; Department of Allergy and Clinical Immunology, Hospices Civils de Lyon, Centre Hospitalier, Lyon Sud, France.
  • Werfel T; Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany.
  • Grond S; Eli Lilly and Company Ltd, Indianapolis, IN, USA.
  • Reed C; Eli Lilly and Company Ltd, Indianapolis, IN, USA.
  • Lampropoulou A; Eli Lilly and Company Ltd, Indianapolis, IN, USA.
  • Tietz N; Eli Lilly and Company Ltd, Indianapolis, IN, USA.
  • Irvine AD; Dermatology Clinic, Our Lady's Children's Hospital Crumlin, Dublin, Ireland.
  • Riedl E; Department of Dermatology, Medical University of Vienna, Vienna, Austria.
J Dermatolog Treat ; 34(1): 2276047, 2023 Dec.
Article en En | MEDLINE | ID: mdl-37965779
INTRODUCTION: We explored patient satisfaction with baricitinib, an oral Janus kinase inhibitor, in patients with atopic dermatitis (AD) treated in routine clinical practice. METHODS: Adults with moderate-to-severe AD treated with baricitinib in clinical practice for ≥4 weeks in France, Germany, and the UK completed a one-time online survey under market research methodologies. Treatment satisfaction was assessed using a Likert scale and abbreviated Treatment Satisfaction Questionnaire for Medication (TSQM-9). Patients reported demographic, disease, and treatment information. Data were analyzed descriptively. RESULTS: The survey was completed by 170 patients with a mean age of 39.3 years (SD = 13.5), 59% (n = 101) were female. At baricitinib initiation, 79% rated their AD as "Severe", yet 28% reported body surface area (BSA) involvement ≥10%. Most were "Satisfied" or "Very satisfied" (76%/18%) with baricitinib, with high rates reported for controlling itch (36%/56%). Itch improvements were noted by 97% of patients. Some tapered/stopped (50%/32%) topical corticosteroid use, aligned with reported improvements on the patient global assessment and BSA. Mean TSQM-9 convenience score was 78.0 (SD = 14.0). CONCLUSIONS: Satisfaction with itch control was particularly high, reflected in rates of improvement in itch since starting baricitinib. On the TSQM-9, the convenience score was the highest. Many patients tapered/stopped concomitant topicals, indicating baricitinib's effect in controlling AD symptoms.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Satisfacción del Paciente / Dermatitis Atópica Límite: Adult / Female / Humans / Male País/Región como asunto: Europa Idioma: En Revista: J Dermatolog Treat Asunto de la revista: DERMATOLOGIA Año: 2023 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Satisfacción del Paciente / Dermatitis Atópica Límite: Adult / Female / Humans / Male País/Región como asunto: Europa Idioma: En Revista: J Dermatolog Treat Asunto de la revista: DERMATOLOGIA Año: 2023 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Reino Unido